NCT04250636View on ClinicalTrials.gov

3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 13, 2020

Primary Completion Date

January 21, 2022

Study Completion Date

February 11, 2022

Conditions
Human Immunodeficiency Virus
Interventions
DRUG

3BNC117-LS

Intravenous infusion of 3BNC117-LS at 30mg/kg

DRUG

10-1074-LS

Intravenous infusion of 10-1074-LS at 30mg/kg

Trial Locations (3)

10021

Weill Cornell Medical Center Clinical Trials Unit-CLOSED SITE, New York

10065

The Rockefeller University, New York

19104

Perelman School of Medicine University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Weill Medical College of Cornell University

OTHER

collaborator

University of Pennsylvania

OTHER

lead

Rockefeller University

OTHER

NCT04250636 - 3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals | Biotech Hunter | Biotech Hunter